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Abstract
Background: The weight-gain caused by many psychotropic drugs is a major cause for poor
compliance with such medications and could also increase cardio-vascular morbidity among
psychiatric patients. Recent reports have shown that the anticonvulsant topiramate causes weight
loss in various patient groups. The drug has also shown effectiveness in open trials as a mood
stabilizer in patients with affective disorders, but not in controlled trials in the acute treatment of
mania. We used topiramate to treat 12 patients with affective disorders who had a body-mass
index >30 kg/m2.
Methods:  Topiramate was prescribed as part of our routine clinical practice, as an add-on
medication, or as a replacement of a mood stabilizer. Patients' weight was recorded in 1 to 2
monthly intervals. Patients were followed up for between 6 and 12 months. The final dose of
topiramate varied from 200 to 600 mg/day.
Results: Topiramate was effective in reducing the weight in 10 out of the 12 patients. At six
months the 12 patients had lost a mean of 7.75 kg (SD = 6.9 kg, p < 0.001) and at 12 months 9
patients had lost a mean of 9.61 kg (SD = 6.7 kg, p = 0.003). Three patients stopped the treatment:
one due to side effects, one due to possible side effects, and one suffered a manic relapse and
showed no sustained weight loss. There were no other clear changes in the course of illness of the
patients.
Conclusion: The evidence of a strong weight-reducing potential of topiramate is indisputable and
clinically significant. Topiramate could be considered in the treatment of bipolar patients who are
overweight, or whose concerns about weight gain compromise their compliance with long-term
prophylactic medication. So far there is no evidence that topiramate has anti-manic effect and it
should not be used as monotherapy.
Background
Psychiatric patients who receive long-term mood-stabiliz-
ing agents can gain excess body weight [1-3]. Weight gain
is induced by the majority of antipsychotics [1,4], lithium
[2,5,6], antidepressants [7] and valproate [5,8,9]. This
could be a major problem with compliance and is one of
the main reasons for discontinuation of treatment [1,10].
Increased body weight is also a major health hazard. Mor-
tality rates for both men and women show a strong asso-
ciation with the body mass index (BMI) [11]. The risk
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starts to increase when the BMI is >25 kg/m2 and doubles
for BMI values of >40 kg/m2, where the correlation curve
becomes progressively steeper [11]. It has been estimated
that obesity causes 300,000 deaths per year in the USA
alone [12].
Topiramate is a relatively new antiepileptic drug. Its
effects include sodium-channel-blocking activity,
enhancement of cerebral GABA concentrations and antag-
onism of AMPA/kainate receptors, which leads to a
decreased glutamate-mediated excitation [13]. It has been
shown to cause weight loss in a variety of treatment pop-
ulations. In an add-on uncontrolled study on 34 epileptic
patients there was a 5.9 kg weight loss at 1 year, while
among the obese patients in that trial (BMI> = 30 kg/m2)
the weight loss reached 10.9 kg [14]. The weight reducing
potential of topiramate has been used to treat obesity in
subjects with no concomitant psychiatric disorder or epi-
lepsy. Bray et al, [15] treated 385 subjects in a ran-
domised, double-blind, placebo-controlled study and
reported weight losses of 4.8%–6.3% of body weight for
increasing doses of topiramate treatment. Topiramate was
also effective in the treatment of binge-eating disorder. In
an open-label study of 13 patients topiramate resulted in
11.8 kg mean weight loss over a period of 3–30 months
[16]. McElroy et al, [17] treated 61 outpatients affected
with binge-eating associated with obesity for 14 weeks in
a placebo-controlled trial. Mean weight loss was 5.9 kg
and the binge-eating frequency was also reduced. The ben-
eficial effects on weight and binge-eating were sustained
during a 42-weeks open continuation of that trial [18],
but a number of patients dropped out from the study.
Another double-blind study on 69 patients with bulimia
nervosa reported improvements in self-esteem and anxi-
ety, in addition to the behavioural dimensions of bulimia
[19].
Several studies have investigated the use of topiramate in
bipolar disorders. Marcotte [20] evaluated 58 psychiatric
patients, mostly with bipolar affective disorder. They were
treated with add-on topiramate for a mean of 16 weeks.
62% were rated improved (weight changes were not
reported). McElroy et al, [21] gave topiramate to 56 out-
patients, either manic, depressed, or euthymic. The manic
patients were reported improved, while the depressed (N
= 11) did not change. Significant decreases in weight and
BMI were recorded at every follow-up point, reaching 6.0
kg after 1 year. Gupta et al [22] performed a retrospective
chart review of 5 patients with bipolar or schizoaffective
disorder and reported a mean weight loss of 10 kg. Vieta
et al, [23] treated 25 patients with treatment-resistant
bipolar spectrum disorders in an open study and reported
significant improvements in rating scales for depression
and mania. Over 50% of all patients were considered to be
responding to topiramate. Ten patients in that study expe-
rienced weight loss. Guille and Sachs, [24] treated 14
patients with refractory bipolar illness for an average of
22.4 weeks. Nine of them (64%) improved. Four patients
with BMI>28 kg/m2 experienced mean weight loss of 13.5
kg. In an open study topiramate was given together with
Risperidone to 58 bipolar patients during a manic epi-
sode, of whom 41 completed the 12 months follow-up
[25]. A significant improvement in rating scales for mania
was recorded and relapse rates were lower compared to
the preceding year. The mean weight of patients decreased
by 1.1 kg by the end of the study. The same team exam-
ined the effect of the co-administration of topiramate and
olanzapine over a 12 months interval [26]. Thirteen
patients completed 12 months of treatment and their
mania and depression ratings improved significantly. At
the endpoint they showed 0.5 kg of weight loss, an
impressive result given the known problems of weight
gain associated with olanzapine [4]. A study using retro-
spective chart review on patients given topiramate showed
a mean loss of 1.2 kg [27]. Topiramate was also used to
treat acute manic episodes. In one study 18 patients with
manic, mixed, or rapid-cycling episodes, resistant to cur-
rent mood-stabilizers were given topiramate [28]. There
were 12 patients who were judged responders after 5
weeks, and they had a mean weight loss of 4.3 kg. In a
study conducted by Grunze et al, [29] 11 patients were
given add-on topiramate, of whom 7 showed good
improvement. In a study reported by Bozikas et al, [30],
14 manic patients received topiramate either as mono-
therapy, or in combination with antipsychotics for 4
weeks. Response rate was 61.5% and all patients tolerated
topiramate well. Both weight loss and weight gain were
reported in that study. Calabrese et al, [31] treated 10
patients hospitalised with mania with topiramate mono-
therapy for 4 weeks and 8 patients were described as
responding. In a retrospective chart review of 76 patients,
13% showed a moderate to marked improvement on the
Clinical Global Impression scale (CGI) [32]. There was a
weight loss in 50% of patients in that sample, with a mean
weight loss of 6.5 kg. A better response and higher weight
loss correlated with higher doses of medication. Topiram-
ate has been used in the treatment of the depressive phase
of bipolar disorder. McIntyre et al, [33] compared bupro-
pion and topiramate in 36 depressed BP outpatients in an
open trial lasting 8 weeks. There was a similarly good
improvement in both groups, with a 56% response rate
on the Hamilton Rating Scale for Depression in the topira-
mate group (N = 18). The weight loss in this study was 5.8
kg in the topiramate group and 6 patients withdrew due
to side effects. Lykouras and Hatzimanolis, [34] gave
topiramate to 56 patients who had suffered relapses of
bipolar disorder in the previous 12 months as an add-on
treatment. There was a significant reduction of new manic
and depressive episodes in the 50 patients who completed
12 months treatment.BMC Psychiatry 2005, 5:19 http://www.biomedcentral.com/1471-244X/5/19
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All these open studies should be considered in the context
of four large unpublished placebo-controlled trials of
topiramate for the treatment of acute mania, which pro-
duced negative results (cited in Yatham [35]). They indi-
cate clearly that monotherapy with topiramate has no
acute anti-manic property. In contrast, almost all of the
above open trials used topiramate as an add-on therapy.
Many patients in our Affective Disorders Clinic were con-
cerned with excessive weight gain which they blamed at
least partly on their treatments. As weight loss was a listed
side effect of topiramate and several small studies had
already reported on its use in bipolar affective disorders,
we decided to use it as an add-on mood stabilizer in
patients who had weight problems. We reasoned that
topiramate could also have mood-stabilizing properties,
like several other anticonvulsants, a finding already
reported in open trials. We also felt that this off-licence
use of topiramate was justified, as this intervention ena-
bled patients to comply better with the rest of their medi-
cation, thus reducing potential relapses of illness, and that
the weight loss could improve their risk for cardio-vascu-
lar disorders. We were not aware of the results from the
controlled trials until all the patients described here were
already taking topiramate.
Patients
Patients in our mood disorders clinic are seen in regular
intervals for long-term maintenance of their illness (some
have attended for over 7 years now). As part of the service
that we provide, patients have regular blood tests, reviews
of medication and checks of weight, usually at intervals of
3 or 4 months. Topiramate was given to some obese
patients as part of our normal clinical practice, rather than
as an experimental intervention (therefore we sought no
Ethics committee approval). We decided to publish our
results only after the patients had taken topiramate for a
considerable time, because we felt that we should share
our experience with other health professionals, as the
results looked so clear. The only difference to treatment as
usual was that we checked the weight of these patients on
a more regular basis than we would have normally done.
All 12 patients included in this report had a pre-topiram-
ate BMI of >30 kg/m2, i.e. they were all obese according to
the National Heart, Lung and Blood Institute guidelines
[36]. According to the British National Formulary guide-
lines [37], an anti-obesity drug should be considered only
for those with a BMI of 30 or greater (page 207), and we
felt that this recommendation should be followed in the
case of Topiramate, even if this drug is not licenced for this
use. The mean BMI of patients at the start was 37.95 kg/
m2, SD = 5.66 and the mean weight was 104.38 kg, SD =
21.46 kg. The patients had the following diagnoses: Bipo-
lar Affective Disorder type I (BPI) = 5, BPII = 4 and Unipo-
lar Depression (UD) = 3. Four of them were rapid cyclers.
Two of the three unipolar patients had co-morbid epi-
lepsy and the third one reached a BMI of nearly 45
(extreme obesity). We felt that it was justified to give her
this medication on general health grounds, although ben-
efits from topiramate on unipolar depression had not
been demonstrated before. Our clinic treats chronic and
treatment resistant patients, and 9 of the 12 patients could
be described as treatment resistant or incomplete
responders, who had either frequent relapses of mood dis-
order (more than 2 per year), or remained chronically
depressed (i.e. had not reached criteria for remission for a
period of at least several weeks over the previous two
years) despite adequate treatment. One more overweight
patient was prescribed topiramate. He did not like its
effect and stopped treatment after one month. He is there-
fore not included in any analysis.
Concomitant medication
The nine treatment resistant/incomplete responder
patients took combinations of medications: all of them
took antidepressants, seven took antipsychotics, five took
lithium and five took anticonvulsants (Table 1). One
other patient was in a full remission on lithium mono-
therapy and one had recently been discharged from hos-
pital after a manic relapse, having been relatively stable
for several years prior to that. In four cases an anticonvul-
sant was exchanged with topiramate, in the remaining
cases topiramate was given as an add-on treatment. No
one received monotherapy of topiramate.
Topiramate dosage
Topiramate dose was increased in steps of 25–50 mg every
one to two weeks. After some of the first patients com-
plained of paraesthesia and headaches, we routinely
started making the increases only at 2-weekly intervals.
The final dose of topiramate ranged between 200 and 600
mg, with a mean of 296 mg. The dose was increased until
we could see a clear effect on the weight, or the patient
reported some side effects. The patient whose topiramate
was increased to 600 mg/day suffers with poorly control-
led epilepsy and we increased the dose in order to achieve
a better seizures control, rather than weight loss.
Statistical analysis
The level of statistical significance for weight loss at each
time-point during the follow-up, compared to baseline,
was determined with a paired-samples t-test. This test
assumes that comparisons at the four time points are
independent, whreas the observations within individuals
are, of course correlated. Therefore the test for statistical
significance is slightly anti-conservative.BMC Psychiatry 2005, 5:19 http://www.biomedcentral.com/1471-244X/5/19
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Results
Weight changes
Patients have received topiramate for between 6 months
and one year by the time of writing this report. Six of them
are still continuing the treatment. The weight changes are
shown in Figure 1 and Table 1. All post-treatment levels
and the pre-treatment levels from the previous two years,
where available, are shown in Figure 1. At 3 and 6 months,
12 patients lost a mean of 4.96 and 7.75 kg respectively.
The nine patients who completed 12 months treatment
showed a weight loss of 10.2 and 9.61 kg at the 9th and
12th month respectively. All these changes are significant
at p < = 0.005.
Side effects
One patient (N 5) noticed thinning of her hair and
stopped the topiramate after six months. This side effect is
known with other mood-stabilizers such as valproate. If
true, it is likely to be quite rare, as it has not been men-
tioned in previous papers, or listed as a side effect. We
submitted a report for a suspected adverse drug reaction to
the Committee on Safety of Medicines in the UK. One
patient (N 10) complained of paraesthesia, sore tongue
and bad taste in her mouth and stopped topiramate dur-
ing an earlier treatment (on Figure 1 this coincides with an
earlier short period of weight loss). She restarted it 7
months later (as her weight had increased again by 5.5
kg). This time the medication was titrated more slowly by
25 mg/day every two weeks and she did not experience
these side effects. This second start of treatment with
topiramate is taken as day 0 for the purposes of this
report, as it was of a longer duration and is still on-going.
One patient (N 2) complained of paraesthesia, later devel-
oped unsteadiness of gait and finally severe Parkinsonism,
therefore most of her medications, including topiramate
were stopped. This patient was taking a number of psy-
chotropic and cardiovascular drugs (a total of nine!), so
we do not know whether topiramate was to blame for her
neurological signs, especially as she had been taking this
drug for over one year already. She recovered completely
around 4 months later and no cause for her condition was
identified, despite numerous investigations and consulta-
tions. We cannot exclude the possibility that topiramate
was at least partially responsible, alone, or in combina-
tion with several other drugs, therefore we report this
event here. Two patients complained of memory and con-
centration problems but preferred to continue with the
medication despite this. These side effects are also well
Table 1: Characteristics of the patients and changes of their weight during the study. Both individual and mean weight changes are 
presented. p-values are based on paired samples tests for the patients who have completed the corresponding follow-up interval. The 
dose of topiramate is the highest dose reached. Under "Concomitant medication" the drugs that are undelined were exchanged with 
topiramate.
Patient N Gender Age DSM-IV Concomitant medication Topirama
te dose 
(mg)
Start Weight change from start (months)
BMI 
(kg/m2)
weight 
(kg)
3
months
6 
months
9
months
12 
months
1 f 49 UD Nortryptiline, carbamazepine 600 42.4 110 -8 -10 -11 -12.5
2 f 48 BPI Risperidone, lamotrigine, 
lofepramine
400 37.2 87 -9.5 -14 -12 -8
3 f 49 BPI Quetiapine, mirtazapine, lithium, 
venlafaxine
2 0 0 4 2 . 3 9 9- 1- 5 - 1 1 - 1 4
4 m 50 BPII Lithium, paroxetine 300 47.7 146 -10.5 -21 -26 -12.5
5 f 28 BPI Lithium 200 31.5 79 -6 -10.5
6 m 31 BPII Lithium, reboxetine, trazodone, 
valproate
300 40.5 120 -6 -7.5 -6.5 -8
7 m 40 BPI Olanzapine, fluoxetine 400 30.3 102.5 -1 +5 -1.5 -5.5
8 f 41 BPII Fluphenazine, carbamazepine, 
paroxetine
250 34.7 90 -7 -14 -18 -22.5
9 f 70 UD Mirtazapine, lithium, amisulpride, 
venlafaxine
200 44.4 116.5 -3 -4 -4 -4
10 f 54 BPII Lithium, clomipramine, 
flupenthixol, trazodone
250 34.7 80 -1.5 -2.5 -2 +0.5
11 f 48 UD Phenelzine, amisulpride, valproate 250 31.0 88.5 -3.5 -8.5
12 m 33 BPI Lithium, carbamazepine 200 38.7 134 -2.5 -1
Mean reduction (kg) 4.96 7.75 10.2 9.61
SD 3.33 6.9 7.98 6.69
p-value 0.001 0.003 0.005 0.003BMC Psychiatry 2005, 5:19 http://www.biomedcentral.com/1471-244X/5/19
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recognised. One patient did not like the appetite suppress-
ing effect of topiramate and stopped it after only one
month, so his data is not analysed in the study.
Clinical changes
We do not perform regular formal ratings of the mood of
our patients. However we regularly record their condition
and changes since the previous appointment. Clear
improvement of the course of illness was noticed only in
one patient (N 3), while eight patients continued to dis-
play a similar pattern of illness, as they had done before
the treatment. None of them was judged to have deterio-
rated. The patients in remission remained well. One
patient (N 12) whose carbamazepine was changed to
topiramate developed a manic episode, therefore we
stopped his topiramate after 6 months and asked him to
resume carbamazepine.
Discussion
This is a naturalistic case-series and the absence of a pla-
cebo control group could have influenced the results. On
the other hand, these patients had already made unsuc-
cessful efforts to lose weight and, as can be seen on Figure
1, their pre-topiramate weight had been either stable, or in
Weight changes in the patients described in the study Figure 1
Weight changes in the patients described in the study. The day of treatment is on the x-axis. The day when topiramate was 
started is day 0 and weight measurements before that point are supplied where available. Each patient's number as referred to 
in the text is given on the right of the figure.BMC Psychiatry 2005, 5:19 http://www.biomedcentral.com/1471-244X/5/19
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most cases had increased steadily during the period of
observation. The weight-reducing potential of topiramate
was impressive in 10 of the 12 patients and the effect was
maintained for the duration of the observation, in most
cases for more than one year. These results are in keeping
with a large body of evidence supporting the weight-los-
ing potential of topiramate, as presented in the Back-
ground. In fact, we could not find a single study that
reported a mean weight gain with topiramate. The weight
loss in our patients was present already at the third month
(mean = 4.96 kg, SD = 3.33, p < 0.001) and continued to
increase at least until the 9th month. Only one patient (N
10) had a weight gain or 0.5 kg at the end of the observa-
tion which still represented an improvement on her ten-
dency to gain weight in the previous years.
Obesity is a very common problem in developed coun-
tries. Its prevalence in the USA is rising and has been esti-
mated at 22.5% among adults aged 20 and over in the
year 2001 [38]. Weight gain is even more prevalent in
bipolar disorder patients [2]. The increased weight in this
population is due to a number of factors, including life-
style and diet, but a major cause is the side effect profile of
the medications that are prescribed long-term for their ill-
ness. If deaths due to suicide and accidents are excluded,
there is still a substantially increased mortality in patients
with mood disorders, which is due mostly to circulatory
disorders [39,40]. Increased weight, high levels of smok-
ing and reduced exercise are likely to be the main factors
leading to such an increased mortality. Health profession-
als cannot just give advice on diet and exercise to over-
weight patients, because the weight gain is to a large extent
caused by the more sedentary life imposed by the illness,
combined with the side effects of the majority of drugs
they are prescribed. Psychiatrists should have a responsi-
bility in managing obesity in their patients by choosing
more appropriate drugs in patients prone to weight gain.
This will bring several benefits: 1) It will improve the
quality of life of their patients, as weight gain is among the
most distressing side effects of psychotropic drugs [41]. 2)
A reduction in weight could increase their life-expectancy,
as weight loss can reduce mortality [1,11]. 3) An
improved weight can increase the adherence to long-term
treatment with mood stabilizers.
Several studies, including this one, show that topiramate
has a strong potential to induce weight loss which is sus-
tained for at least one year. Despite the side effects
reported in this and other studies, topiramate is generally
well tolerated. Most of the patients in our series who com-
plained of side effects, still preferred to continue the treat-
ment, as they liked its overall effect. In our experience it is
very unusual to have such a high rate of patients who con-
tinue to take a new medication. The effect on memory and
concentration should however receive closer examination
in future studies.
The main unanswered question is whether topiramate has
any mood-stabilizing properties, like other anticonvul-
sants such as carbamazepine, valproate and lamotrigine.
Open studies for maintenance treatment in bipolar disor-
der and in the acute treatment of mania have so far been
encouraging (as reviewed in the Background). However,
four large unpublished placebo-controlled monotherapy
trials failed to confirm the efficacy of topiramate in the
treatment of acute mania (cited in [35]), indicating a poor
antimanic effect, at least in monotherapy. Our work was
not designed to examine any mood-stabilizing properties
of topiramate, as we did not use regular mood charts, the
period of 12 months is too short to evaluate long-term
benefits on the pattern of episodes, and there was no com-
parison group. In addition, many of our patients were
already talking a combination of mood stabilizers with-
out complete treatment effect, having failed to achieve a
long-term stability on a variety of treatments that had
been tried over the years. In view of that, we did not expect
any clear improvements in the mood or course of illness
of this patient population. All we can conclude so far is
that topiramate does not appear to be superior to other
mood stabilizers in the long-term treatment of patients
with treatment resistant affective disorders. One of our
patients had a manic relapse after we changed his car-
bamazepine with topiramate (he was also receiving regu-
lar lithium prophylaxis). In addition, we would like to
report that topiramate was given to two more patients in
our clinic who had a BMI of <30 kg/m2 and are therefore
not presented as part of this case-series. These two patients
had refused to take other mood-stabilizing drugs for fear
of weight gain and only agreed to take topiramate as mon-
otherapy, having heard that it will not cause weight gain.
Both of them suffered relapses of mania, which necessi-
tated the addition of atypical antipsychotics and admis-
sion to hospital. Although these three observations are
anecdotal, they strengthen the impression that topiramate
monotherapy does not have antimanic effect. Whether
topiramate has any effect on the depressive side of bipolar
illness is not yet know.
Conclusion
Topiramate appears a very useful drug for weight reduc-
tion in patients with bipolar disorders. The mood stabiliz-
ing effect of topiramate is however questionable. The very
different results obtained from the controlled mono-
therapy trials of topiramate in mania and the open add-on
trials summarised in the Background indicate that topira-
mate should not be prescribed as monotherapy in bipolar
disorders as it has no acute antimanic effect. In our opin-
ion the current place of topiramate in the treatment of
affective disorders is as an add-on treatment for patientsBMC Psychiatry 2005, 5:19 http://www.biomedcentral.com/1471-244X/5/19
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who experience clinically significant weight gain, which
could either compromise their physical health, or influ-
ence them to stop taking established mood stabilizers.
Recommendations
Topiramate should not be used in monotherapy and
unless new research shows otherwise, psychiatrists should
assume that it has no mood-stabilizing properties.
Dose titration
Topiramate dose should be increased gradually and in
two-weekly intervals.
Cognitive function
Topiramate is known to cause neurocognitive side effects.
Psychiatrists should monitor their patients carefully for
the emergence of such side effects.
Pregnancy
As with most other mood-stabilizers (anticonvulsants and
lithium), women who may become pregnant should be
warned of the possible consequences of taking such drugs
during pregnancy [37].
Adequate hydration
Patients should be advised to ensure adequate hydration,
especially if they are predisposed to nephrolithiasis [37].
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